Table 3. Influence of different clinical and pathological factors on 5-year DFS and OS.

Variable	No. of All patients	Local Recurrence		Distant Metastasis		All Failure		5-Years DFS Rate	P	5-Year OS Rate	P
		No.	%	No.	%	No.	%
	4121	351	8.5%	973	23.6%	1215	29.5%	69.5%		75.2%
Gender
Male	2352	219	9.3%	553	23.5%	713	30.3%	68.7%	0.081	74.9%	0.762
Female	1769	132	7.5%	420	24.7%	502	29.4%	70.6%		75.5%
Age, year
≤60	2312	173	7.5%	535	24.1%	652	29.2%	71.5%	0.087	78.0%	<0.0001
>60	1809	178	9.8%	438	24.2%	563	31.1%	66.9%		71.5%
Tumor location
Colon	1449	34	2.3%	364	25.1%	381	26.3%	73.2%	0.065	76.1%	0.132
Rectum	2671	317	11.9%	609	22.8%	834	31.2%	67.4%		74.7%
Tumor size, diameter
≤5.0 cm	2866	240	8.4%	670	23.4%	835	29.1%	70.1%	0.654	75.8%	0.251
>5.0 cm	1254	111	8.9%	303	24.1%	380	30.3%	68.2%		73.9%
Preoperative CEA levels
<5.0 ng/ml	2479	98	8.4%	463	18.7%	610	24.6%	75.0%	<0.0001	80.7%	<0.0001
≥5.0 ng/ml	1161	198	8.0%	401	34.5%	454	39.1%	58.6%		64.3%
Unknown	481	55	11.4%	109	22.7%	151	31.4%	67.0%		72.0%
Preoperative CA199 levels
<29.0 u/ml	2820	32	7.0%	490	20.8%	601	26.5%	73.1%	<0.0001	81.3%	<0.0001
≥29.0 u/ml	459	169	7.2%	179	39.0%	195	42.5%	54.9%		54.5%
Unknown	842	55	6.5%	109	12.9%	151	17.9%	80.2%		72.0%
pT category (7th)
pT 2	128	8	6.2%	20	15.6%	26	20.3%	78.5%	<0.0001	82.8%	<0.0001
pT 3	2851	141	8.1%	253	14.4%	353	20.2%	79.2%		83.4%
pT 4	2242	202	9.0%	700	31.2%	836	37.3%	61.3%		68.1%
pN category (7th)
pN 0	2070	106	5.1%	252	12.2%	332	16.0%	83.6%	<0.0001	87.9%	<0.0001
pN 1a	533	39	7.3%	121	22.7%	149	28.0%	71.4%		74.3%
pN 1b	539	43	8.0%	187	34.7%	215	39.1%	57.8%		64.8%
pN 1c	282	42	14.9%	47	16.7%	87	30.9%	69.9%		75.2%
pN 2a	374	56	15.0%	171	45.7%	207	55.3%	39.5%		50.1%
pN 2b	323	65	20.1%	195	40.6%	225	69.7%	25.8%		32.9%
npN category
npN 0	2070	106	5.1%	252	12.2%	332	16.0%	83.6%	<0.0001	87.9%	<0.0001
npN 1a	526	32	6.1%	116	22.1%	141	26.8%	72.4%		76.2%
npN 1b	629	51	8.1%	179	28.5%	207	22.9%	65.6%		69.1%
npN 2a	495	72	14.5%	198	40.0%	252	50.9%	45.7%		57.9%
npN 2b	401	90	22.4%	228	56.9%	283	60.6%	26.0%		37.1%
Tumor deposits (TDs)
Positive	717	131	18.3%	281	39.2%	389	54.3%	44.6%	<0.0001	57.7%	<0.0001
Negative	3404	220	6.5%	692	20.3%	826	24.3%	74.9%		78.9%
Venous invasion
Yes	268	47	17.5%	136	50.7%	157	58.6%	36.8%	<0.0001	45.7%	<0.0001
No	3853	304	7.9%	837	21.7%	1058	27.5%	71.7%		77.1%
Lymphatic invasion
Yes	26	8	30.8%	10	38.5%	16	61.5%	29.2%	<0.0001	35.6%	<0.0001
No	4095	343	9.4%	963	23.5%	1199	29.3%	69.8%		75.4%
Differentiation grade
Well	452	22	4.9%	54	11.9%	73	16.2%	82.7%	<0.0001	88.2%	<0.0001
Moderately	3213	275	8.6%	725	22.6%	922	28.7%	70.4%		75.8%
Poorly	456	54	11.8%	194	42.5%	220	48.2%	50.0%		57.8%
Pathological category
Papillary or tubular adenocarcinoma	3856	325	8.4%	888	23.0%	1121	29.1%	69.9%	<0.0001	75.9%	<0.0001
Mucinous adenocarcinoma	220	20	9.1%	63	28.6%	68	30.9%	68.2%		70.1%
Signet ring cell cancer	45	6	13.7%	22	49.9%	26	57.8%	40.8%		41.5%
Histological type
Protrude	2733	230	8.4%	561	20.5%	722	26.4%	73.0%	<0.0001	78.5%	<0.0001
Ulcer	1151	98	8.5%	322	28.0%	386	33.5%	64.8%		70.1%
Infiltrative	237	23	9.7%	90	38.0%	107	45.1%	52.1%		61.2%
Adjuvant therapy
Yes	2796	228	8.2%	672	24.0%	825	29.5%	70.1%	0.361	76.7%	0.002
No	1325	123	9.3%	301	22.7%	390	29.4%	68.2%		71.8%